Catequentinib
Refractory Plasma Cell Neoplasm
Small moleculePhase 2Dormant
CCC
53/ 100
Provisional rating · Methodology v0.2
Rating breakdown
- Clinical Evidence
- 38/ 100
- Competitive Position
- 95/ 100
Competitive context
0 Active assets in the Refractory Plasma Cell Neoplasm cohort.
| Asset / Sponsor | Phase | Rating |
|---|---|---|
FLUTICASONE National Cancer Institute (NCI) | Phase 2 | B |
Evomela National Cancer Institute (NCI) | Phase 2 | B |
Sargramostim National Cancer Institute (NCI) | Phase 2 | B |
Keyhole Limpet Hemocyanin National Cancer Institute (NCI) | Phase 2 | B |
FILGRASTIM National Cancer Institute (NCI) | Phase 2 | B |
View all 9 →
Same molecule, other indications
Catequentinib is also rated in:
Are you the sponsor?
Submit your data room for a Verified Rating. The public-data rating remains visible alongside.
Contact →